BAM15 vs SANA (MVD1)
updated
BAM15 (tier C) vs SANA (MVD1) (tier B): what each is, why each got its grade, half-life and source counts side by side.
BAM15 · tier C
a preclinical mitochondrial protonophore that reduced fat gain and improved metabolic measures in mice, with no human exposure, dose-finding, or safety study.
tier rationale
C-tier reflects a coherent mechanism and a strong integrated mouse paper with oral PK, dose-ranging, metabolic efficacy, and acute tolerability work. It cannot rise to B because no human has been studied, no human PK exists, and the class mechanism carries safety questions that animal temperature measurements cannot settle.
SANA (MVD1) · tier B
an investigational nitroalkene small molecule that targets creatine-kinase-dependent thermogenesis, with mouse fat-loss data, a small exploratory 15-day human weight signal, and a high-dose renal safety signal in phase 1.
tier rationale
B-tier reflects direct human PK and safety data, a small exploratory 15-day human weight signal, and a substantial mechanistic and animal-efficacy paper. It does not rise to A because the 41-person program was phase 1 rather than a confirmatory efficacy trial, and two of three participants at the highest single dose developed renal tubular injury. Long-term efficacy and safety remain unresolved.
at a glance
| BAM15 | SANA (MVD1) | |
|---|---|---|
| tier | C | B |
| category | weight loss | weight loss |
| sources | 2 | 1 |
| claims evaluated | 4 | 4 |
| half-life | 1.7 hours in mouse plasma after 10 mg/kg oral gavage; no human half-life | approximately 1.6 to 2.0 hours in the first-in-human oral phase 1 study |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.